CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype

CYP2C19 is a drug-metabolising enzyme involved in the metabolism of a number of chemotherapeutic agents including cyclophosphamide. Variants of the CYP2C19 gene result in a loss of function polymorphism, which affects approximately 3% of the Caucasian population. These individuals are poor metabolis...

Descripción completa

Detalles Bibliográficos
Autores principales: Helsby, N A, Lo, W-Y, Sharples, K, Riley, G, Murray, M, Spells, K, Dzhelai, M, Simpson, A, Findlay, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570511/
https://www.ncbi.nlm.nih.gov/pubmed/18854824
http://dx.doi.org/10.1038/sj.bjc.6604699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570511/
https://www.ncbi.nlm.nih.gov/pubmed/18854824
http://dx.doi.org/10.1038/sj.bjc.6604699

Ejemplares similares